Essential hypertension
Conditions
Interventions
Experimental group:Oral trial drug bisoprolol amlodipine (Kang Xin'an)
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years with essential hypertension; 2. Taking any of the following free combination at least 4 weeks prior to study start: (1) Bisoprolol 2.5 mg/d + Amlodipine 5 mg/d; (2) Bisoprolol 2.5 mg/d + Levamlodipine 2.5 mg/d; (3) Metoprolol plain 12.5 mg, bid + Amlodipine 5 mg/d; (4) Metoprolol plain 12.5 mg, bid + Levamlodipine 2.5 mg/d; (5) Metoprolol SR 23.75 mg/d + Amlodipine 5 mg/d; (6) Metoprolol SR 23.75 mg/d + Levamlodipine 2.5mg/d; 3. Uncontrolled blood pressure: SBP >= 140 mmHg and/ or DBP >= 90 mmHg (at office); 4. Seated resting heart rate >= 70 bpm (at office).
Exclusion criteria
Exclusion criteria: 1. Medical history: Tumor, hyperthyroidism and atrial fibrillation; 2. Pregnant and nursing females; 3. Contraindications to bisoprolol and amlodipine; 4. Concomitant antihypertensive medications; 5. Any significant disease, which, in Investigators opinion, would have excluded the subject from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Office Blood Pressure;Office Blood Pressure control rate; | — |
Countries
China
Contacts
Public ContactWenli Cheng
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed